41 results on '"Ozelo, Margareth"'
Search Results
2. Utilizing artificial intelligence for the detection of hemarthrosis in hemophilia using point-of-care ultrasonography
3. Health-related quality of life following valoctocogene roxaparvovec gene therapy for severe hemophilia A in the phase 3 trial GENEr8-1
4. A review of the rationale for gene therapy for hemophilia A with inhibitors: one-shot tolerance and treatment?
5. Recombinant factor IX Fc for major surgery in hemophilia B: factor IX plasma activity levels and effective hemostasis
6. Post hoc longitudinal assessment of the efficacy and safety of recombinant factor IX Fc fusion protein in hemophilia B
7. First study of extended half-life rFVIIIFc in previously untreated patients with hemophilia A: PUPs A-LONG final results
8. Gynecologic and obstetric management of women with von Willebrand disease: summary of 3 systematic reviews of the literature
9. ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease
10. Prolonged APTT of unknown etiology: A systematic evaluation of causes and laboratory resource use in an outpatient hemostasis academic unit
11. Impact of prophylaxis on health‐related quality of life of boys with hemophilia: An analysis of pooled data from 9 countries
12. Extending recombinant factor IX Fc fusion protein dosing interval to 14 or more days in patients with hemophilia B
13. Eradication of neutralizing antibodies to factor VIII in canine hemophilia A after liver gene therapy
14. von Willebrand disease: proposing definitions for future research
15. Chronic Disease Outcomes As Predictors of Quality of Life in Patients with Hemophilia Α: Data from the Real-World AHEAD International Study
16. Incidence of Inhibitors in Previously Untreated Patients with Severe Hemophilia a Treated with Plasma-Derived Vs. Recombinant Factor VIII Concentrates: A Systematic Review and Meta-Analyses
17. Impact of novel hemophilia therapies around the world
18. AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B
19. Relationship between Endogenous, Transgene FVIII Expression and Bleeding Events Following Valoctocogene Roxaparvovec Gene Transfer for Severe Hemophilia A: A Post-Hoc Analysis of the GENEr8-1 Phase 3 Trial
20. Effectiveness and Safety Outcomes in Patients with Hemophilia a Receiving Antihemophilic Factor (Recombinant) for at Least 5 Years in a Real-World Setting: 6-Year Interim Analysis of the Ahead International and German Studies
21. The Pro-Adhesive and Reduced Angiogenic Properties of Endothelial Colony Forming Cells (ECFC) from JAK2V617F MPN Patients Are Not Related to the Expression of the JAK2 mutation in These Cells: A Potential Role of ADAM17
22. Vinorelbine-Based Hematopoietic Stem-Cell Mobilization: A More Effective, Low-Cost Alternative to Conventional Chemotherapy
23. Proliferative Sickle Cell Retinopathy in SS and SC Hemoglobinopathies: Identification of New Candidate Genes
24. Somatic Mutations Associated with Myeloid Transformation of RUNX1 -Mutated Familial Platelet Disorders with Propensity to Myeloid Malignancies Using Targeted Next-Generation Sequencing
25. Evaluation of Predictors of Outcome in Immune Tolerance Induction Treatment of Hemophilia Α Patients with High-Responding Inhibitors
26. Safety and Efficacy of Turoctocog Alfa in Prevention and on-Demand Treatment of Bleeding Episodes in Patients with Hemophilia A
27. Immune Tolerance Induction Treatment Is Cost-Effective in Adult Patients with Long-Standing High-Responding Inhibitors
28. Low Bleeding Rates with Increase or Maintenance of Physical Activity in Patients Treated with Recombinant Factor IX Fc Fusion Protein (rFIXFc) in the B-LONG and Kids B-LONG Studies
29. Extended-Interval Prophylaxis with rFIXFc in Adults and Adolescents with Hemophilia B: Interim Results of the B-YOND Extension Study
30. Perioperative Management of Hemostasis with Recombinant FIX Fc Fusion Protein in Subjects Undergoing Surgery in the B-YOND Study
31. Differential Diagnosis of Hereditary and Acquired Thrombocytopenia By the Immature Platelet Fraction and Thrombopoietin Levels
32. Changes in Annualized Bleeding Rate over Time and Relationship with Dosing of Turoctocog Alfa during the guardian™ Program
33. Predicting FIX Activity in Prophylaxis Patients Using Recombinant FIX Fc Fusion Protein for Treatment of Bleeding Episodes
34. Pharmacokinetics, Safety, and Efficacy Of Long-Lasting Recombinant Factor IX Fc Fusion Protein (rFIXFc) In Adolescent Subjects With Hemophilia B: A Subgroup Analysis Of The B-LONG Study
35. Comparative Evaluation of Five Different Assays for Ristocetin Cofactor Activity Determination,
36. Adhesive and Inflammatory Properties Are Increased in Blood Outgrowth Endothelial Cells From Patients with Sickle Cell Anemia
37. Six Novel Mutations Identified in the Glycoproteins Ib Alpha, Ib Beta and IX Genes Among Twenty-Two Unrelated Patients with Bernard-Soulier Syndrome in Brazil
38. Genetically-Engineered Endothelial Cells Implanted Into the Omentum of Hemophilia A Dogs Provides Long-Term Circulating FVIII Resulting From Sustained FVIII Expression and Persistent Cell Viability.
39. Induction of Immune Tolerance to Canine FVIII in Hemophilia a Dogs with Inhibitors Using AAV-Mediated Expression of Canine FVIII
40. Long-Term Phenotypic Correction of Hemophilia A Mice Following Intravenous Injection of miRNA-Regulated Lentiviral Vectors.
41. Efficacy, Safety and Economic Evaluation of Recombinant Activated Factor VII (rFVIIa) in the Management of Mild and Moderate Bleedings in Haemophilia Patients with Inhibitors in Brazil.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.